Participant‐reported pain relief of 50% or greater · Patients with pain after surgical removal of lower wisdom teeth (third molars) requiring bone removal or with baseline moderate to severe…
Ibuprofen (single postoperative oral dose; 200 mg to 512 mg) leads to higher proportion of patients with >50% maximum pain relief (TOTPAR) over 6… compared with paracetamol (acetaminophen) (single postoperative oral dose; 600 mg… (high certainty).
1 finding from 1 review
Proportion of patients with >50% maximum pain relief (TOTPAR) over 2 hours · Patients with pain after surgical removal of lower wisdom teeth (third molars) requiring bone removal or with baseline moderate to severe…
Ibuprofen (single postoperative oral dose; 200 mg to 512 mg) leads to higher proportion of patients with >50% maximum pain relief (TOTPAR) over 2… compared with paracetamol (acetaminophen) (single postoperative oral dose; 600 mg… (high certainty).
1 finding from 1 review
Patients not using rescue medication at 6 hours · Patients with pain after surgical removal of lower wisdom teeth (third molars) requiring bone removal or with baseline moderate to severe…
Ibuprofen (single postoperative oral dose; 200 mg to 512 mg) leads to higher patients not using rescue medication at 6 hours compared with paracetamol (acetaminophen) (single postoperative oral dose; 600 mg… (high certainty).
1 finding from 1 review
All cause mortality · people with cancer who have febrile neutropenia
beta‐lactam monotherapy showed no clear difference in all cause mortality compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Any nephrotoxicity ‐ Ag dosing regimen (Copy) · people with cancer who have febrile neutropenia
beta‐lactam monotherapy leads to lower any nephrotoxicity ‐ Ag dosing regimen (Copy) compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Clinical failure—same beta lactam Antibiotic modifications · people with cancer who have febrile neutropenia
beta‐lactam monotherapy probably leads to higher treatment failure ‐ same beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (moderate certainty).
1 finding from 1 review
Treatment failure ‐ different beta‐lactam · people with cancer who have febrile neutropenia
beta‐lactam monotherapy may leads to lower treatment failure ‐ different beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (low certainty).
1 finding from 1 review
Overall survival among all patients · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival among all patients compared with primary surgery (high certainty).
1 finding from 1 review
Presence of tumor‐free resection margin · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in presence of tumor‐free resection margin compared with primary surgery (moderate certainty).
1 finding from 1 review
Tumor stage at resection (T0 to T2 vs T3 to T4) · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to higher tumor stage at resection (T0 to T2 vs T3 to T4) compared with primary surgery (moderate certainty).
1 finding from 1 review
Tumor stage at resection (N0 vs N+) · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy may leads to higher tumor stage at resection (N0 vs N+) compared with primary surgery (low certainty).
1 finding from 1 review
Postoperative morbidity RD · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
1 finding from 1 review
Postoperative mortality RD · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
1 finding from 1 review
Disease-free survival · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in disease‐free survival (landmark time 6 months) compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by type of data ‐ Individual patient data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by type of data ‐ Individual patient data compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by type of data ‐ Aggregated data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by type of data ‐ Aggregated data compared with primary surgery (moderate certainty).
1 finding from 1 review
Overall survival by tumor site ‐ Esophagus · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Esophagus compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by tumor site ‐ GE junction · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by tumor site ‐ GE junction compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by tumor site ‐ Stomach · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Stomach compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by chemo‐/radiotherapy ‐ Chemotherapy only compared with primary surgery (high certainty).
1 finding from 1 review